Introduction: Acute myeloid leukemia (AML) is the most common acute forms of leukemia in
adults. It has a poor long-term survival with a high relapse rate and at relapse, is commonly …

Immunotherapy is a milestone in the treatment of poor-prognosis pediatric acute
lymphoblastic leukemia (ALL) and is expected to improve treatment outcomes and reduce …

Resistance to chemotherapy plays a significant role in cancer mortality. To identify genetic
units affecting sensitivity to cytarabine, the mainstay of treatment for acute myeloid leukemia …

Background Acute myeloid leukemia (AML) remains a devastating disease with a 5-year
survival rate of less than 30%. AML treatment has undergone significant changes in recent …

Adenosine compartmentalization has a profound impact on immune cell function by
regulating adenosine localization and, therefore, extracellular signaling capabilities, which …

Acute myeloid leukemia (AML) can display de novo or acquired resistance to cytosine
arabinoside (Ara-C), a primary component of induction chemotherapy. To identify genes …

Acute myeloid leukemia (AML) patients display dismal prognosis due to high prevalence of
refractory and relapsed disease resulting from chemoresistance. Treatment protocols …

Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy with
complex heterogenous genetic and biological nature. Thus, prognostic prediction and …

We sought to identify drugs that could counteract cytarabine resistance in acute myeloid
leukemia (AML) by generating eight resistant variants from MOLM-13 and SHI-1 AML cell …

Resistance to xenobiotic nucleosides used to treat acute myeloid leukemia (AML) and other
cancers remains a major obstacle to clinical management. One process suggested to …